Tax Inversion Action? Clock Ticks on Pfizer-Allergan Merger – ValueWalk Premium
Tax Inversion Pfizer-Allergan Merger

Tax Inversion Action? Clock Ticks on Pfizer-Allergan Merger

As the Pfizer-Allergan merger talks heat up, shining yet another spotlight on the tax inversion issue, a Goldman Sachs report notes that it is up to the U.S. Treasury and IRS to stem flood of corporations fleeing the U.S. tax system for more friendly climates abroad.

Pfizer / Allergan acquisition would result in a tax inversion, as clock is ticking
If drug giant Pfizer Inc. is successful in . . .


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email or click Chat.

Saved Articles
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.